Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab

CONTEXT: Pituitary carcinoma is a rare and aggressive malignancy with a poor prognosis and few effective treatment options. CASE: A 35-year-old woman presented with an aggressive ACTH-secreting pituitary adenoma that initially responded to concurrent temozolomide and capecitabine prior to metastasiz...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Endocrinol Metab
Asıl Yazarlar: Lin, Andrew L, Jonsson, Philip, Tabar, Viviane, Yang, T Jonathan, Cuaron, John, Beal, Katherine, Cohen, Marc, Postow, Michael, Rosenblum, Marc, Shia, Jinru, DeAngelis, Lisa M, Taylor, Barry S, Young, Robert J, Geer, Eliza B
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Endocrine Society 2018
Konular:
Clinical Research Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6456994/
https://ncbi.nlm.nih.gov/pubmed/30085142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2018-01347
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller